Nervonik
Nervonik, Inc. is a clinical-stage medical device company in Los Angeles, California, founded in 2020 by CEO Aydin Babakhani, developing miniaturized peripheral nerve stimulation (PNS) neuromodulation implants for chronic neuropathic pain in high-motion anatomy. Its platform pairs proprietary wireless power delivery and miniaturized implantable leads with integrated sensing circuitry that records evoked compound action potentials (ECAPs) and other biomarkers, enabling closed-loop, patient-specific stimulation as an opioid-free alternative to spinal cord stimulators and pharmacological therapy. The company completed a first-in-human feasibility study and closed an oversubscribed $52.5M Series B in April 2026 led by Amzak Health, after a $13M Series A in March 2025. Nervonik publishes no developer program, public API, SDK, or machine-readable API contract; its public web surface is a WordPress marketing and investor-relations site.
Nervonik is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Neuromodulation, Neurotechnology, and Health.
Nervonik’s developer surface includes engineering blog, support, and 9 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Nervonik Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 1
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.